Z Biotech is significantly impacting glycobiology and glycomics markets by providing its leading carbohydrate products and services to biotech and pharmaceutical companies, as well as leading research institutes. Z Biotech’s advantage lies in increasing the accuracy and efficiency for analysis of carbohydrates (or glycans) and their binding partners in therapeutic biologics, medicines and biosimilars, as well as producing glycosylation profiling for biological samples and therapeutic biologics.

Following on the explosive impact from the genomics and proteomics era, glycomics is a new and important field for studying carbohydrate modification of proteins and protein-glycan interactions. Z Biotech’s glycan microarray and lectin microarray platforms are built on its proprietary microarray substrates which can create sensitive and multivalent detection of protein-glycan interactions. The current glycan libraries in Z Biotech represent glycan structures in mammalian, human and bacteria, including N-glycans, O-glycans, ganglioside head-group glycans, blood group glycans, human milk glycans, glycosaminoglycan glycans, and bacterial glycans.

Currently, this type of analysis of protein-glycan interaction and glycosylation is expensive and inefficient, leaving a huge gap for analysis of protein-glycan interaction and glycosylation in high-throughput solutions. To solve the issue of low efficiency and high cost of current ELISA microplate-based analysis, we offer diverse cost-effective microarray-based solutions.